Lihong Chen

2.1k total citations
50 papers, 1.7k citations indexed

About

Lihong Chen is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Lihong Chen has authored 50 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 18 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Lihong Chen's work include Cancer-related molecular mechanisms research (9 papers), RNA modifications and cancer (7 papers) and MicroRNA in disease regulation (5 papers). Lihong Chen is often cited by papers focused on Cancer-related molecular mechanisms research (9 papers), RNA modifications and cancer (7 papers) and MicroRNA in disease regulation (5 papers). Lihong Chen collaborates with scholars based in China, United States and Australia. Lihong Chen's co-authors include William S. Lane, Yu Pan, Daniele M. Gilkes, Jiandong Chen, Michael Ristow, Andrew W. Norris, Alison C. Jozsi, Laurie J. Goodyear, C. Ronald Kahn and Michael F. Hirshman and has published in prestigious journals such as Advanced Materials, Journal of Clinical Investigation and The EMBO Journal.

In The Last Decade

Lihong Chen

50 papers receiving 1.7k citations

Peers

Countries citing papers authored by Lihong Chen

Since Specialization

Citations

This map shows the geographic impact of Lihong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lihong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lihong Chen more than expected).

Fields of papers citing papers by Lihong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lihong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lihong Chen. The network helps show where Lihong Chen may publish in the future.

Co-authorship network of co-authors of Lihong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Lihong Chen. A scholar is included among the top collaborators of Lihong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lihong Chen. Lihong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ALKBH5 SUMOylation-mediated FBXW7 m6A modification regulates alveolar cells senescence during 1-nitropyrene-induced pulmonary fibrosis 2024 ·Journal of Hazardous Materials ·(unknown), Ningning Kang, Rongrong Wang, Meng‐Die Li, Lihong Chen, Peng Zhou, De‐Xiang Xu, Hui Zhao, Lin Fu	20
2	Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in Clinics 2023 ·Advanced Materials ·Zehong Yang, Lihong Chen, Ji Liu, Hua Zhuang, Wei Lin, (unknown), Xiaojun Zhao	32
3	Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·Huawei Cai, Li Zhao, Qiuxiao Shi, Hao Yang, Xiao Liu, Mufeng Li, (unknown), Xiaoai Wu, (unknown), Lihong Chen, Lin Li, Xiaofeng Lu	5
4	Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition 2023 ·Chemico-Biological Interactions ·(unknown), Nengwen Ke, Ziyao Wang, (unknown), Bin Xiang, Zhengkun Zhang, (unknown), (unknown), (unknown), (unknown), Xubao Liu, Fang Xie, (unknown), Dan Chen, (unknown), Wenbing Wu, Lihong Chen, Huawei Cai, Ji Liu	10
5	Long non-coding RNA MYU promotes ovarian cancer cell proliferation by sponging miR-6827-5p and upregulating HMGA1 2023 ·Pathology & Oncology Research ·Shaoyu Wang, (unknown), Jinhua Wang, (unknown), Lihong Chen	5
6	Identification of the effect and mechanism of Yiyi Fuzi Baijiang powder against colorectal cancer using network pharmacology and experimental validation 2022 ·Frontiers in Pharmacology ·Bin Xiang, (unknown), Zhengkun Zhang, (unknown), (unknown), Lihong Chen, Ji Liu	10
7	Usnic Acid Inhibits Proliferation and Migration through ATM Mediated DNA Damage Response in RKO Colorectal Cancer Cell 2020 ·Current Pharmaceutical Biotechnology ·Wenbing Wu, (unknown), (unknown), (unknown), (unknown), (unknown), Dan Chen, (unknown), Lihong Chen, Ji Liu	14
8	20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progression 2020 ·Archives of Biochemistry and Biophysics ·Jiaojiao Lu, Yuanyuan Zhou, Xia Zheng, Lihong Chen, Xiaoqian Tuo, Hong Chen, Mei Xue, Qian Chen, Wei Chen, Xu Li, Le Zhao	20
9	Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway 2018 ·Drug Design Development and Therapy ·Lihong Chen, Jinhua Wang, Jianbo Wu, (unknown), (unknown)	33
10	Vigilin interacts with CTCF and is involved in the maintenance of imprinting of IGF2 through a novel RNA–mediated mechanism 2017 ·International Journal of Biological Macromolecules ·Xiaoqin Yu, Qiuying Liu, (unknown), Yuan Huang, Lei Jiang, Xiaoyan Xie, Ji Liu, Lihong Chen, Ling Wei, Yang Qin	9
11	Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway 2016 ·Toxicology in Vitro ·(unknown), Lihong Chen, Yuxian Shen, Jianming Xu	33
12	Current trends in PGE2 targeting for anti-inflammatory therapy. 2016 ·Lihong Chen	5
13	Dataset for the quantitative proteomics analysis of the primary hepatocellular carcinoma with single and multiple lesions 2015 ·Data in Brief ·Xiaohua Xing, Yao Huang, Sen Wang, (unknown), Yongyi Zeng, Lihong Chen, Ling Li, Jinhua Zeng, (unknown), Xiao Han, Jingfeng Liu, Xiaolong Liu	8
14	Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells 2012 ·Oncology Reports ·(unknown), Lihong Chen, Xiaobing Han, Jia Wang, Jue Wang	56
15	Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064 2009 ·Bioorganic & Medicinal Chemistry Letters ·Jonathan Y. Bass, Richard D. Caldwell, Justin A. Caravella, Lihong Chen, Katrina L. Creech, David N. Deaton, Kevin P. Madauss, Harry B. Marr, Robert B. McFadyen, Aaron B. Miller, Derek J. Parks, Dan Todd, Shawn P. Williams, G. Bruce Wisely	45
16	Species and control of insect pests and major diseases of Torreya grandis merrillii 2006 ·Frontiers of Forestry in China ·(unknown), (unknown), Xiulong Chen, (unknown), Suping Li, (unknown), (unknown), (unknown), Lihong Chen	1
17	ATM and Chk2‐dependent phosphorylation of MDMX contribute to p53 activation after DNA damage 2005 ·The EMBO Journal ·Lihong Chen, Daniele M. Gilkes, Yu Pan, William S. Lane, Jiandong Chen	202
18	Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones 2003 ·Journal of Clinical Investigation ·Andrew W. Norris, Lihong Chen, Simon J. Fisher, Ildikó Szántó, Michael Ristow, Alison C. Jozsi, Michael F. Hirshman, Evan D. Rosen, Laurie J. Goodyear, Frank J. Gonzalez, Bruce M. Spiegelman, C. Ronald Kahn	354
19	Nuclear exclusion of p53 in a subset of tumors requires MDM2 function 2000 ·Oncogene ·Wenge Lu, Radhika Pochampally, Lihong Chen, (unknown), Yiliang Wang, (unknown)	72
20	A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells 1998 ·Oncogene ·Radhika Pochampally, (unknown), Lihong Chen, Weijian Shao, Edward A. Levine, (unknown)	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact